Palm Beach Post

RadSite Webinar: Virtual Supervision & Remote Scanning on the Administration of IV Contrast in CT & MRI Imaging

ANNAPOLIS, MD, UNITED STATES, March 5, 2026 /EINPresswire.com/ — RadSite™, a leading accreditation agency promoting safety and quality in imaging, will host a ...
Healio

FDA approves Ambelvist MRI contrast agent with lower dose of gadolinium

The FDA has approved Ambelvist, a macrocyclic gadolinium-based option for contrast-enhanced MRI, now the lowest ...
Las Vegas Sun

Bayer’s AMBELVIST® (gadoquatrane) Receives FDA Approval for Contrast-Enhanced MRI to Detect and Visualize Lesions with Abnormal Vascularity in the Central Nervous System and ...

AMBELVIST ® (gadoquatrane) is a gadolinium-based contrast agent indicated in adult and pediatric patients, including term neonates, for use with magnetic resonance imaging (MRI) to detect and ...
Nasdaq

GE Healthcare Announces U.S. FDA Approval of Macrocyclic MRI Contrast Agent Clariscan™ (gadoterate meglumine) Injection for Intravenous Use

Clariscan, approved in more than 55 countries globally with over four million patient doses shipped, is now FDA-approved in the U.S. Expands the GE Healthcare portfolio of contrast media products “The ...
Becker's Hospital Review

FDA clears low-dose MRI contrast agent for use in neonates, infants

The FDA has approved Bracco’s gadopiclenol-based contrast agent, Vueway, for IV MRI imaging in neonates and infants. Vueway is a macrocyclic gadolinium-based contrast agent that delivers effective ...
Business Wire

International Contrast Ultrasound Society (ICUS) and Northwest Imaging Forums announce partnership to advance IV training for sonographers

CHICAGO--(BUSINESS WIRE)--The International Contrast Ultrasound Society (ICUS) and Northwest Imaging Forums (NWIF) today announced an educational partnership to help train sonographers to perform ...
Business Wire

GE Healthcare Announces U.S. FDA Approval of Macrocyclic MRI Contrast Agent Clariscan™ (gadoterate meglumine) Injection for Intravenous Use

CHALFONT ST GILES, England--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) has approved Clariscan™, a macrocyclic, ionic, gadolinium-based, MRI contrast agent, expanding the GE ...